



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/159

January 13, 2026

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 050 Scrip Symbol – Biocon
--	--

Dear Sir/Madam,

Subject: Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors

Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 12, 2026, *inter alia*, to approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2025.

Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company read with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company has been closed from Thursday, January 01, 2026 to Saturday, February 14, 2026 (both days inclusive). Accordingly, the trading window will open on Sunday, February 15, 2026.

The Company will organize an Earnings Conference Call for Analysts and Investors on Friday, February 13, 2026. The details of the same are enclosed herewith.

The above-mentioned information will also be available on website of the Company at www.biocon.com.

Request you to take the above intimation on record.

Thanking you,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328



20th K.M. Hosur Road, Electronics City, Bengaluru 560 100

January 13, 2026

Biocon's Q3 FY 2025-26 Earnings Conference Call

At 09:00 hrs. IST on February 13, 2026

The management team of Biocon Limited (BSE code: 532523, NSE ID: BIOCON) will **organize a conference call for Analysts and Investors** following the announcement of financial results for the quarter and nine months ended December 31, 2025. The call will be conducted over Zoom.

Conference Call Details	
Date	Friday, February 13, 2026
Time	09:00 hrs IST
Registration Link	Click here
Recording	<ul style="list-style-type: none">• Audio recording will be made available before the next trading day or within 24 hrs from the end of the call, whichever is earlier• Video recording will be made available within 48 hrs from the end of the call• Access the recordings on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings)
Conference Call Transcript	Will be made available within 5 working days of the conclusion of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts)

Note: Participants are requested to join 10 minutes before the scheduled start time of the call.

For further information please contact:

Prashant Nair

Investor Relations – Biocon Biologics Limited

P: +91 80 2808 2040/ +91 98200 95476

E: prashant.nair@biocon.com

Safe Harbor: Certain statements that may be made in the conference call may be forward-looking based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and overseas, and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, nor any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in the conference call.